Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

TG 003, Tocris Bioscience™

Catalog No. p-4816716 Shop All R&D Systems Products
Click to view available options
Quantity:
10 mg
50 mg
This item is not returnable. View return policy
This item is not returnable. View return policy

Potent inhibitor of Clk-family kinases; also inhibits DYRK1A/B

Potent, ATP-competitive inhibitor of Clk-family kinases (IC50 values are 15, 20 and 200 nM for mClk4, 1 and 2 respectively and >10 μM for mClk3). Also inhibits DYRK1A/B (IC50 values are 24 and 34 nM respectively). Suppresses serine/arginine-rich protein phosphorylation; affects the regulation of alternative splicing by phosphorylation of SR protein both in vitro and in vivo.

Chemical Identifiers

CAS 719277-26-6
Molecular Formula C13H15NO2S
Molecular Weight (g/mol) 249.328
InChI Key BGVLELSCIHASRV-QPEQYQDCSA-N
Synonym clk inhibitor, clk inhibitor, tg003, z-1-3-ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene propan-2-one, 1z-1-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene propan-2-one, cdc2-like kinase inhibitor, tg003, z-1-3-ethyl-5-methoxybenzo d thiazol-2 3h-ylidene propan-2-one, cdc2-like kinase inhibitor, 1-2z-3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene propan-2-one, d06mbi, 1-3-ethyl-5-methoxy-2 3h-benzothiazolylidene-2-propanone
PubChem CID 1893668
IUPAC Name (1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one
SMILES CCN1C2=C(C=CC(=C2)OC)SC1=CC(=O)C

Specifications

Quantity 10 mg
Formula Weight 249.33
Percent Purity >98%
Chemical Name or Material TG 003
Recommended Storage Store at +4°C
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.